-
Wendy Williams and Bruce Willis Both Battling Same Dementia Type: 'She Maintains Her Trademark Sense Of Humor'
Thursday, February 22, 2024 - 10:50pm | 562Read More...Wendy Williams, the renowned talk show host, has been diagnosed with dementia, the same type that actor Bruce Willis is battling, as per a statement issued on her behalf, according to a report. What Happened: Williams has been diagnosed with primary progressive aphasia and frontotemporal dementia....
-
Donald Trump's Mix-Up Of Nikki Haley, Nancy Pelosi Sees 'Dementia Don' Trend On Social Media: 2024 Election Could Be Battle 'Between Demented And Dementia'
Wednesday, January 24, 2024 - 2:33pm | 991Read More...A rematch of the 2020 presidential election could be what voters will head to the polls to decide in the November 2024 presidential election. Donald Trump and Joe Biden continue to lead their respective parties in the race and could give voters little choice but to select a candidate who could...
-
Former First Lady Rosalynn Carter Diagnosed With Dementia
Tuesday, May 30, 2023 - 4:24pm | 423Read More...Former First Lady Rosalynn Carter, a longtime advocate for expanded access to mental health care, has been diagnosed with dementia, the Carter Center announced Tuesday. “She continues to live happily at home with her husband, enjoying spring in Plains and visits with loved ones,”...
-
Alector Stock Falls After Flashing 12-Month Data From Mid-Stage Trial In Frontotemporal Dementia Patients
Thursday, July 29, 2021 - 1:52pm | 313Read More...Alector Inc (NASDAQ: ALEC) detailed early data from its lead drug, AL001, INFRONT-2 Phase trial at the Alzheimer's Association International Conference (AAIC 2021) Patients with one type of frontotemporal dementia decline because they're missing one copy of an immune-...
-
Anavex Life Sciences Stock Jumps As Blarcamesine Shows Convincing Biomarker-Correlating Efficacy Data In Parkinson's Disease Dementia Patients
Monday, June 28, 2021 - 9:10am | 305Read More...Anavex Life Sciences Corp (NASDAQ: AVXL) has reported that SIGMAR1 mRNA expression correlates positively with responses in efficacy endpoints in the Phase 2 trial of ANAVEX 2-73 (blarcamesine) in patients with Parkinson's disease dementia. ANAVEX 2-73 activates the sigma-1...
-
Voyager Therapeutics' Vectorized Anti-Tau Antibody Shows Encouraging Preclinical Data In CNS Disorders
Wednesday, May 12, 2021 - 10:20am | 245Read More...Voyager Therapeutics Inc (NASDAQ: VYGR) has announced new preclinical data characterizing the durable expression and activity of a vectorized anti-tau antibody. The results will be presented at the American Society of Gene and Cell Therapy. Data demonstrate durable expression...
-
After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock Drivers
Tuesday, April 6, 2021 - 5:36pm | 694Read More...ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares came under pressure Monday after the Food and Drug Administration (FDA) rejected its regulatory application seeking label expansion for its dementia drug. The Acadia Analysts: Goldman Sachs analyst Salveen Richter downgraded Acadia shares...
-
Aptinyx Stock Is Trading Higher After Restarting NYX-458 Study In Dementia Associated Cognitive Impairment
Tuesday, April 6, 2021 - 6:57am | 214Read More...Aptinyx Inc (NASDAQ: APTX) has restarted patient screening in a Phase 2 study evaluating NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson's disease and dementia with Lewy bodies. Aptinyx will release the data from this...
-
Acadia Stock Drops After FDA CRL For Pimavanserin Application In Hallucinations and Dementia-Related Psychosis
Monday, April 5, 2021 - 7:22am | 354Read More...The FDA has issued a Complete Response Letter (CRL) to Acadia Pharmaceuticals Inc (NASDAQ: ACAD) regarding its supplemental marketing application (for Nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP...
-
FDA Gives Accelerated Review Tag To BioXcel's BXCL501 In Dementia-Related Agitation
Monday, March 15, 2021 - 9:06am | 206Read More...The FDA has designated Breakthrough Therapy status to BioXcel Therapeutics Inc's (NASDAQ: BTAI) BXCL501, to treat agitation associated with dementia. The designation intends to expedite the development and review of certain product candidates. After a routine review of...
-
BioXcel's BXCL501 Lower Dose Shows Statistical Significance On Agitation Scales
Wednesday, March 3, 2021 - 10:49am | 297Read More...BioXcel Therapeutics Inc (NASDAQ: BTAI) plans to finalize study design, dosing, and endpoints for its BXCL501 Phase 3 program in dementia-related agitation. The end of the Phase 2 meeting with the FDA is scheduled in Q2 2021. BXCL501 is an orally dissolving thin film formulation of...
-
Intra-Cellular Therapies Discloses New Drug Candidate For Dementia Related Episodes
Wednesday, February 24, 2021 - 11:42am | 289Read More...Intra-Cellular Therapies Inc (NASDAQ: ITCI) expands its pipeline with a new molecular entity, ITI-1284, a sublingually delivered deuterated form of lumateperone. ITI-1284 has been developed in collaboration with Catalent Inc (NYSE: CTLT), using its...
-
After A Freefall In Axovant Shares, Chardan Upgrades
Wednesday, January 10, 2018 - 12:45pm | 390Read More...Axovant Sciences Ltd (NASDAQ: AXON)'s announcement this week that its lead drug candidate intepirdine failed in a late-stage trial comes after the stock lost 90 percent of its value over the past three months following a negative announcement on an Alzheimer's trial. The Analyst...
-
Anavex Announces Positive Phase 2A Data On Alzheimer's Treatment, Shares Rally
Tuesday, November 22, 2016 - 10:35am | 256Read More...Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) surged more than 20 percent in Tuesday’s pre-market after it announced positive data from its Phase 2a study in mild-to-moderate Alzheimer’s patients. “At 41 weeks, Alzheimer’s patients taking a daily oral dose of ANAVEX 2-...
-
Biotie Therapies Making Strides In Neurodegenerative Diseases
Wednesday, June 10, 2015 - 12:50pm | 887Read More...Finnish Biotech company Biotie Therapies (NASDAQ: BITI) (OTC: BIOZF) hopes to raise $56 million in its upcoming IPO this Friday, June 12. The company will offer 3.8 ADSs at price of $14.82, up 12 percent from its original offer. The deal was initially set for 3.4 million ADSs at the same price...













